Key result
CYP2D6 genotype significantly affects metoprolol metabolism during long-term therapy, with adjusted plasma concentrations 6.2-fold higher in poor metabolizers than extensive metabolizers (P<0.01).
Why the study?
Does the CYP2D6 genotype affect metoprolol plasma concentrations and metabolic ratio during long-term treatment?
Observational (n=91)
Does the CYP2D6 genotype affect metoprolol plasma concentrations and metabolic ratio during long-term treatment?
Effect estimate: 6.2-fold higher (*0/*0) and 3.9-fold higher (intermediate)
p-value: p=< 0.0001
The pronounced effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term therapy, leading to significantly higher plasma concentrations in poor and intermediate metabolizers.
No takes yet. Share an insight, caveat, or question.
May inform metoprolol dosing in poor metabolizers; leaves open impact on clinical outcomes.
Rau et al. (2002) conducted an observational in Patients on long-term treatment with metoprolol (n=91). Metoprolol vs. CYP2D6 fully functional alleles (*1 and *2) was evaluated on Plasma metabolic ratio of metoprolol/alpha-OH-metoprolol (6.2-fold higher (*0/*0) and 3.9-fold higher (intermediate), p=< 0.0001). CYP2D6 genotype significantly affects metoprolol metabolism during long-term therapy, with adjusted plasma concentrations 6.2-fold higher in poor metabolizers than extensive metabolizers (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: